FIT PROTOCOL · CURRENT RECORD

Interactions

Folder 01

Part IV · The Four Interaction Cascades

Safety & Clinical
  • The operational record is sound.
  • Risk concentrates in four interactions, not in any single ingredient.
  • Read this matrix before changing any dose.
Protocol reference
#CascadeComponents and summed doseMechanismPractical consequence
1 Piperine drug-clearance inhibition TESTOFX BioPerine 9.5 mg + Curcumin BioPerine 5 mg = 14.5 mg/day (training days) Inhibits intestinal P-glycoprotein and hepatic CYP3A4 plus phase-II glucuronidation Raises systemic exposure to co-administered drugs and to the stack itself. Disclose to prescribers.
2 ALA to insulin autoimmune syndrome R-ALA 300 mg + glycogen-depleted training + only 19 g carbohydrate in V4 Health Canada flags alpha-lipoic acid for IAS (Hirata disease) in HLA-DRB1*0406 / *0403 carriers Hypoglycaemia symptoms post-training need glucose awareness, not stimulant escalation.
3 Osmotic GI stack without a gallbladder Magnesium 341-646 mg + high-dose vitamin C + continuous bile trickle Osmotic water draw compounds bile-related stool looseness Loose stools are predictable system output; log and moderate fat bolus before blaming single foods.
4 Stimulant stack at the ceiling IGNITER about 373 mg caffeine + TeaCrine (theacrine half-life 16-20 h) + Dynamine + theobromine + Earl Grey 40-70 mg Overlapping methylxanthine exposure across the day Exposure regularly crosses the 400 mg/day guidance; sleep is the limiting organ.

Minerals & Micros

POJECT / DOCUMENT LIBRARY

Books & manuals